Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q6Q4G3
UPID:
AMPQ_HUMAN
Alternative names:
CHL2 antigen; Laeverin
Alternative UPACC:
Q6Q4G3; A8K6J0; C9JGD2; Q32MR1; Q4G0I9; Q4G0V2; Q86XA3; Q8NBZ2
Background:
Aminopeptidase Q, also known as Laeverin or CHL2 antigen, is a metalloprotease with a pivotal role in placentation. It regulates the biological activity of essential peptides at the embryo-maternal interface, demonstrating a preference for substrates like Leu-4-methylcoumaryl-7-amide. Its enzymatic activity includes cleaving the N-terminal amino acid of peptides such as angiotensin-3, kisspeptin-10, and endokinin C.
Therapeutic significance:
Understanding the role of Aminopeptidase Q could open doors to potential therapeutic strategies.